Health
Cancer Prevention
Female CEOs
Iovance Biotherapeutics
$19.739876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$19.73
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.25 (-1.25%) As of 2:28 PM EDT today
-$0.25 (-1.25%) Today
Why Robinhood?
You can buy or sell IOVA and other stocks, options, ETFs, and crypto commission-free!
About IOVA
Iovance Biotherapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. Read More The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
CEO
Employees
88
Headquarters
San Carlos, California
Founded
2007
Market Cap
2.47B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
1.33M
High Today
$20.10
Low Today
$19.44
Open Price
$19.95
Volume
1.28M
52 Week High
$26.59
52 Week Low
$7.26
Collections
Health
Cancer Prevention
Female CEOs
Biotechnology
Medical
Therapy
Technology
2013 IPO
Price Paid on Robinhood
72% Higher
Right Now
52 Week Low
$7.26
Average Price Paid
$11.50
52 Week High
$18.25
Analyst Ratings
100%
of 9 ratings
Buy
100%
Hold
0%
Sell
0%
IOVA Earnings
-$0.38
-$0.34
-$0.31
-$0.27
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
—
Actual
Expected Oct 31, After Hours